Metabolic engineering Corynebacterium glutamicum for D-chiro-inositol production.
World J Microbiol Biotechnol
; 40(5): 154, 2024 Apr 03.
Article
en En
| MEDLINE
| ID: mdl-38568465
ABSTRACT
D-chiro-inositol (DCI) is a potential drug for the treatment of type II diabetes and polycystic ovary syndrome. In order to effectively synthesize DCI in Corynebacterium glutamicum, the genes related to inositol catabolism in clusters iol1 and iol2 were knocked out in C. glutamicum SN01 to generate the chassis strain DCI-1. DCI-1 did not grow in and catabolize myo-inositol (MI). Subsequently, different exogenous and endogenous inosose isomerases were expressed in DCI-1 and their conversion ability of DCI from MI were compared. After fermentation, the strain DCI-7 co-expressing inosose isomerase IolI2 and inositol dehydrogenase IolG was identified as the optimal strain. Its DCI titer reached 3.21 g/L in the presence of 20 g/L MI. On this basis, the pH, temperature and MI concentration during whole-cell conversion of DCI by strain DCI-7 were optimized. Finally, the optimal condition that achieved the highest DCI titer of 6.96 g/L were obtained at pH 8.0, 37 °C and addition of 40 g/L MI. To our knowledge, it is the highest DCI titer ever reported.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Corynebacterium glutamicum
/
Diabetes Mellitus Tipo 2
/
Inositol
Límite:
Female
/
Humans
Idioma:
En
Revista:
World J Microbiol Biotechnol
Año:
2024
Tipo del documento:
Article
País de afiliación:
China